Zentalis Pharmaceuticals (ZNTL) Change in Accured Expenses (2019 - 2026)

Zentalis Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$1.5 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 63.93% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was -$14.7 million, a 116.95% decrease from a year earlier, with the FY2025 full-year figure at -$17.3 million, up 3.92% from the prior year.
• Change in Accured Expenses slipped to -$1.5 million in Q1 2026 per ZNTL's latest filing, from -$733000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $11.8 million in Q2 2024 and bottomed at -$15.2 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is -$1.4 million (2023), against an average of -$608411.8.
• Biggest YoY gain for Change in Accured Expenses was 368.48% in 2024; the steepest drop was 980.72% in 2024.
• Year by year, Change in Accured Expenses stood at $5.0 million in 2022, then jumped by 105.88% to $10.4 million in 2023, then tumbled by 124.64% to -$2.6 million in 2024, then surged by 71.39% to -$733000.0 in 2025, then slumped by 97.95% to -$1.5 million in 2026.
• Per Business Quant, the three latest ZNTL Change in Accured Expenses figures stand at -$1.5 million (Q1 2026), -$733000.0 (Q4 2025), and -$2.0 million (Q3 2025).